IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will present at the 42nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco today at 9:45 AM PT (12:45 PM ET). Executive leadership will provide a company overview followed by a fireside chat.

德克萨斯州欧文市——（商业新闻短讯）——麦克森公司（纽约证券交易所代码：MCK）将于今天上午9:45（美国东部时间下午12:45）出席在旧金山威斯汀圣弗朗西斯酒店举行的第42届摩根大通医疗保健年会。高管层将提供公司概况，然后在炉边聊天。

The audio webcast will be available live at McKesson’s Investor Relations website at investor.mckesson.com, along with the company’s slide presentation.

该音频网络广播将在麦凯森的投资者关系网站Investor.McKesson.com上进行现场直播，以及公司的幻灯片演示。

McKesson’s Board of Directors Elects Kevin Ozan as New Director

麦凯森董事会选举凯文·奥赞为新董事

The McKesson board of directors has elected Kevin Ozan as director and member of the Audit Committee and Finance Committee, effective January 8, 2024. With the election of Ozan, McKesson’s board of directors increases from 11 to 12 members, 11 of whom are independent.

麦凯森董事会选举凯文·奥赞（KevinOzan）为董事兼审计委员会和财务委员会成员，自2024年1月8日起生效。随着Ozan的当选，McKesson的董事会成员从11人增加到12人，其中11人是独立的。

“We’re pleased to welcome Kevin to the McKesson Board,” said Donald Knauss, McKesson’s independent board chair. “His extensive executive leadership background in strategy and finance will be instrumental as the company continues to deliver on its growth initiatives, advancing health outcomes for all.”.

麦克森独立董事会主席唐纳德·克纳斯（DonaldKnauss）表示：“我们很高兴欢迎凯文加入麦克森董事会。”。“他在战略和财务方面拥有广泛的高管领导背景，这将有助于公司继续实施其增长计划，促进所有人的健康。”。

Ozan recently retired from his role as senior executive vice president of strategic initiatives at McDonald’s Corporation. During his 25-year tenure with the global food service retailer, Ozan also served as executive vice president and chief financial officer and held multiple leadership roles overseeing financial and investor relations teams.

Ozan最近辞去了麦当劳公司战略计划高级执行副总裁的职务。在这家全球食品服务零售商的25年任期内，Ozan还担任执行副总裁兼首席财务官，并担任多项领导职务，监督财务和投资者关系团队。

Prior to McDonald’s, he worked for over a decade in Ernst & Young’s audit and mergers and acquisitions practices..

在加入麦当劳之前，他在安永会计师事务所（Ernst&Young）的审计和并购业务中工作了十多年。。

In addition to McKesson, Ozan currently serves on the board of Cineworld, a private company with one of the largest global cinema businesses. Ozan holds a bachelor’s degree in accounting from the University of Michigan and a master’s degree in business from the Kellogg School of Management at Northwestern University..

除麦凯森外，奥赞目前还在电影世界（Cineworld）董事会任职，这是一家拥有全球最大电影公司之一的私人公司。Ozan拥有密歇根大学会计学学士学位和西北大学凯洛格管理学院商学硕士学位。。

McKesson Acquires Compile

McKesson收购Compile

On January 4, 2024, McKesson acquired Compile, a healthcare data platform that aggregates and integrates data from across the US healthcare system to characterize providers and their patient panels. The acquisition is anticipated to provide a centralized commercial data platform for McKesson and accelerate its capabilities in commercializing data and providing insights to biopharma customers..

2024年1月4日，McKesson收购了Compile，这是一个医疗保健数据平台，它汇总并整合了来自美国医疗保健系统的数据，以表征提供者及其患者小组的特征。此次收购预计将为McKesson提供一个集中的商业数据平台，并加速其数据商业化的能力，并为生物制药客户提供见解。。

About McKesson Corporation

关于McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable.

McKesson Corporation是一家多元化医疗服务的领导者，致力于为世界各地的患者改善健康状况。我们的团队与生物制药公司、护理提供者、药店、制造商、政府和其他人合作，提供见解、产品和服务，以帮助使优质护理更容易获得和负担得起。

Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories..

在McKesson.com上了解更多关于McKesson如何影响医疗保健的各个方面，并阅读我们的故事。。

Cautionary Statements

警示性声明

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the negative of these words or other comparable terminology.

本新闻稿包含《1933年证券法》第27A节和《1934年证券交易法》第21E节所指的前瞻性声明。前瞻性陈述可以通过使用术语来识别，例如“相信”，“期望”，“预期”，“可能”，“将”，“应该”，“寻求”，“大约”，“打算”，“项目”，“计划”，“估计”，“目标”或这些单词的否定词或其他类似术语。

The discussion of expectations and integration of Compile may also include forward-looking statements. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by law, we undertake no obligation to update or revise our forward-looking statements.

对Compile的期望和集成的讨论也可能包括前瞻性陈述。读者不应过度依赖前瞻性报表，如财务业绩预测，这些报表仅在首次发布之日起生效。除法律要求外，我们没有义务更新或修改我们的前瞻性声明。

Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases..

前瞻性陈述涉及风险和不确定性，可能导致实际结果与预测、预期或暗示的结果存在重大差异。虽然不可能预测或识别所有此类风险和不确定性，但我们鼓励投资者阅读我们向证券交易委员会提交的公开文件和新闻稿中描述的风险因素。。

These risk factors include, but are not limited to: we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we might experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we might not realize expected benefits from business process initiatives; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we may be unsuccessful in achieving our strategic growth objectives; we might be unable to successfully complete or integrate acquisitions or other business combinations; our technology products or services might not conform to specifications or perform as we intend; our contracts with government entities involve future funding and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to limitations that could impede the growth of our data services business; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we might be adversely impacted by changes or disruptions in product supply and have difficulties in sourcing or selling products due to a variety of causes; we might be adversely impacted as a result of our distribution of generic pharmaceuticals; we might be adversely impacted by changes in the economic environments in which we operate; changes affecting capita.

这些风险因素包括但不限于：我们经历了代价高昂且具有破坏性的法律纠纷和解决方案，包括我们在分销阿片类药物等受管制物质方面的作用；我们可能会遭遇保险或赔偿未涵盖的损失；我们受制于不断变化、广泛、复杂且具有挑战性的医疗保健和其他法律；我们不时记录从减值到商誉、无形资产和其他长期资产的重大费用；我们可能无法实现业务流程计划的预期收益；我们遇到的网络安全事件可能会严重损害我们的技术系统或导致重大数据泄露；我们可能无法实现战略增长目标；我们可能无法成功完成或整合收购或其他企业合并；我们的技术产品或服务可能不符合规范或不符合我们的预期；我们与政府实体的合同涉及未来的资金和合规风险；我们可能会因与供应商的关系或合同发生变化而受到损害；我们对第三方数据的使用受到可能阻碍我们数据服务业务增长的限制；我们可能会受到医疗改革的不利影响，例如定价和报销模式的变化；我们可能会受到竞争和行业整合的不利影响；我们可能会受到产品供应变化或中断的不利影响，并且由于各种原因在采购或销售产品方面存在困难；由于我们分销仿制药，我们可能会受到不利影响；我们经营的经济环境的变化可能会对我们产生不利影响；影响资本的变化。